We are a fully integrated biotechnology company dedicated to developing breakthrough therapies that address significant unmet clinical needs.
Our expertise spans discovery, engineering, CMC and clinical development.
By using our proprietary AutoRegulation (AR) platform, we can create powerful next-generation therapies that are also remarkably safe. Our technology ensures durable clinical efficacy by precisely controlling and self-regulating the therapeutic effect. This not only mitigates severe toxicities often seen with conventional treatments but also leads to improved long-term patient outcomes.
Discovery and Engineering
Applying our industry-leading engineering capabilities to our next generation therapeutics using our AutoRegulation platform ensures our pipeline products can achieve the maximum efficacy in clinic whilst crucially maintaining the highest levels of patient safety.
Our discovery efforts also extend to novel pipeline products targeting unique disease specific antigens creating new treatment opportunities in areas of huge unmet need. These therapies aim to overcome the challenges of the disease microenvironment and provide effective and safe treatment opportunities for a broader range of conditions.
CMC
We are committed to developing efficient manufacturing processes that reduce the cost of goods, ensuring our high-quality products can be made globally available.
With our own process and analytical development capability we are able to rapidly develop, industrialise and transfer processes and analytics to our partners for clinical manufacture, testing, and release, ensuring that drug product supply remains off the critical path for our clinical ambitions.
Clinical Agility
Our proactive and nimble approach to drug discovery and development unlocks the potential of our portfolio. This allows us to rapidly advance our pre-clinical pipeline into the clinic and use our expertise and flexibility to maximise our understanding of our drugs, ultimately benefiting patients.
More in this section
Our technologies
We are changing the paradigm of cancer therapy with our immunotherapy technology.
Auto-regulation
NovalGen’s proprietary ground-breaking autoregulation technology platform enables the maximum efficacy to be unleashed from a therapy whilst ensuring a manageable safety profile by limiting life threatening toxicities.
